H.B. Fuller (NYSE: FUL) receives $1.2bn Ancora bid for Building Adhesives unit

Ancora Holdings Group, a Cleveland-based activist that has spent the past three months publicly opposing H.B. Fuller Company’s push into medical adhesives, escalated its campaign on Tuesday with an unsolicited cash proposal to acquire H.B. Fuller’s Building Adhesive Solutions (BAS) segment for between $1.1 billion and $1.2 billion. H.B. Fuller (NYSE: FUL), the St. Paul-based specialty adhesives maker, confirmed receipt of the letter and said its board would evaluate the proposal with financial and legal advisers. The offer arrives seven weeks after H.B. Fuller unveiled a recommended £715 million cash acquisition of United Kingdom-based Advanced Medical Solutions Group plc, a transaction Ancora had publicly urged the board to abandon. The central tension for shareholders is no longer whether to build a specialty medical adhesives platform, but whether to sell the most cyclical piece of the existing portfolio at a full multiple to accelerate deleveraging and end an escalating governance dispute, or defend a segment that just posted 9.4 percent second-quarter revenue growth.

What did Ancora Holdings actually propose to H.B. Fuller’s board on August 12?

Ancora, which manages roughly $11.7 billion in assets and holds a stake of more than 2 percent in H.B. Fuller, said its proposal is an all-cash bid for the Building Adhesive Solutions segment at $1.1 billion to $1.2 billion. The firm said it first approached H.B. Fuller privately on July 7, 2026, and made the proposal public through a letter to the board signed by Ancora Chairman and Chief Executive Officer Fred DiSanto and Ancora Alternatives President James Chadwick. The proposed transaction would be subject to H.B. Fuller board and shareholder approvals, governmental and third-party consents, Hart-Scott-Rodino antitrust waiting-period expiration, confirmatory due diligence and negotiation of a definitive agreement. Ancora said it is highly confident in its ability to secure any necessary financing and that the offer would not include a financing contingency. The firm is working with Olshan Frome Wolosky LLP as legal adviser and unnamed operating partners, and said it would require only a customary due diligence window given what it described as extensive prior familiarity with the segment.

The letter itself was combative. DiSanto and Chadwick argued that a sale would help H.B. Fuller reduce leverage, allow management to focus on integrating the pending Advanced Medical Solutions acquisition, exit what they called a low-margin business in a fragmented market and, in their phrasing, solidify a potentially indefinite end to public activism. They also accused the board of entrenchment, writing that they feared its collective preference for entrenchment was again impairing its judgment and undermining shareholder interests. H.B. Fuller’s response was procedural rather than substantive, noting only that the board reviews its portfolio regularly and would evaluate the offer with advisers.

Why is Ancora offering $1.1 billion to $1.2 billion for the Building Adhesive Solutions segment now?

The timing is deliberate. H.B. Fuller created the Building Adhesive Solutions segment, or BAS, at the start of fiscal 2025 by combining its Insulated Glass, Woodworking and Composites businesses with its Roofing, Building Envelope and Infrastructure operations after divesting its Flooring business. The company disclosed at the time that the combined BAS operations generated roughly $850 million in fiscal 2024 net revenue and approximately $130 million in adjusted EBITDA. BAS therefore represents a well-defined, ring-fenced operating unit with a discrete P&L, a discrete asset base and a discrete management structure, which makes it far easier to price and carve out than a business woven across an integrated cost structure.

The segment’s recent trajectory sharpens Ancora’s argument in two directions at once. On the growth side, BAS reported second-quarter fiscal 2026 revenue of $245.2 million, up 9.4 percent year on year, and first-half revenue of $427.0 million, roughly 25 percent of company revenue. That makes it the most attractive it has been in some time to potential buyers, which supports a fuller multiple. On the strategic side, however, Ancora is arguing that construction adhesives is the least defensible piece of H.B. Fuller’s portfolio, more exposed to housing and commercial construction cycles than the Hygiene, Health and Consumable Adhesives and Engineering Adhesives segments, and structurally lower-margin than either. A cyclical peak is precisely when an activist wants a divestment discussion opened.

How does the Ancora proposal collide with H.B. Fuller’s Advanced Medical Solutions acquisition?

The bid cannot be read in isolation from the AMS transaction. On June 25, 2026, H.B. Fuller announced a recommended cash offer to acquire Advanced Medical Solutions, a UK-listed medical-products specialist focused on tissue-healing technologies, at £2.85 per AMS share, valuing AMS at roughly £715 million. H.B. Fuller disclosed at that point that pro forma net leverage following completion of the AMS acquisition would rise to approximately 4.0 times net debt to adjusted EBITDA, or 3.7 times including run-rate synergies. It set a public target of returning to its 2.5 to 3.0 times leverage range within two years of closing.

Ancora had opposed the AMS deal from the outset. In a May 23 letter, DiSanto and Chadwick described the proposed acquisition as a quasi-transformational international acquisition that they said was completely out of management’s depth, and reminded shareholders that H.B. Fuller had earlier committed publicly to pausing on closing deals in the near term while deleveraging. That commitment came from Chief Executive Officer Celeste Mastin on the first-quarter fiscal 2026 earnings call, when management said it would prioritise share repurchases and target 2.5 to 3.0 times net debt to adjusted EBITDA. When the board proceeded with AMS regardless, Ancora issued a public condemnation on June 24 and signalled a proxy fight at the 2027 annual meeting. The August 12 bid effectively repositions the campaign from opposition to proposal, giving the activist a specific transaction the board must now formally evaluate rather than a general grievance about capital allocation.

What would a BAS divestment mean for H.B. Fuller’s post-AMS leverage and capital position?

Applying Ancora’s numbers to H.B. Fuller’s own disclosures illustrates why the offer is calibrated at this size. H.B. Fuller ended the second quarter of fiscal 2026 with net debt of roughly $1.9 billion and net debt to adjusted EBITDA of 3.1 times, an improvement from 3.4 times a year earlier. Management’s full-year fiscal 2026 guidance calls for adjusted EBITDA of $650 million to $675 million and adjusted diluted earnings per share of $4.60 to $4.90. The AMS acquisition is being funded entirely with debt through fully committed financing, which is what takes pro forma leverage to the disclosed 4.0 times at close.

An all-cash sale of BAS at the middle of Ancora’s range would generate roughly $1.15 billion of gross proceeds, with pro forma group EBITDA falling by whatever BAS is currently contributing, likely in the $130 million to $150 million range on a run-rate basis given segment revenue growth. Applied against management’s stated 4.0 times pro forma leverage arithmetic post-AMS, a net-of-tax use of proceeds to reduce debt could bring leverage back inside the 2.5 to 3.0 times target range meaningfully faster than the two-year deleveraging plan the company outlined at the time of the AMS announcement. That accelerated deleveraging path, along with a portfolio simplified around Hygiene, Health and Consumable Adhesives, Engineering Adhesives and the incoming medical business, is the strategic case Ancora is trying to force the board to consider.

How does the $1.1 to $1.2 billion price compare with what BAS actually earns for H.B. Fuller?

The valuation math is where the debate becomes genuinely contestable rather than cosmetic. Using the $130 million adjusted EBITDA figure H.B. Fuller cited when it created BAS, Ancora’s range implies an enterprise-value multiple of roughly 8.5 to 9.2 times fiscal 2024 EBITDA. On a forward view, if BAS is now running above that level given first-half revenue growth, the effective multiple compresses somewhat. Either way, the offer sits above typical trading multiples for fragmented building products businesses and is broadly consistent with recent specialty-chemicals divestment transactions where the target has secular tailwinds and clean carve-out boundaries.

That said, whether $1.1 billion to $1.2 billion is fair value or a discount depends heavily on the assumptions applied to BAS’s mid-cycle margin trajectory. H.B. Fuller has publicly targeted a group adjusted EBITDA margin above 20 percent over a three to five year horizon, and BAS is one of the segments management has repeatedly said it is repositioning. Sellers typically want to be paid for the strategic optionality that comes with owning a segment through the next commercial cycle, particularly one management has already spent significant restructuring capital reshaping. The H.B. Fuller board can credibly argue that Ancora is trying to acquire a fully restructured platform just before the pricing and volume benefits fully materialise, and that intrinsic value is above the top of the disclosed range. Ancora can equally argue that $1.2 billion in cash today is more accretive to shareholders than uncertain execution over three years. Neither side of that debate is provably correct until the board runs a market check.

What execution and regulatory risks sit between the bid and any completed transaction?

Even assuming H.B. Fuller’s board is willing to engage, execution risk is material and cuts in several directions. The BAS segment was itself only assembled at the start of fiscal 2025, which means shared services, information-technology systems, procurement contracts and cross-segment personnel arrangements are unlikely to be fully separable without disentanglement work. A carve-out sale typically requires transition service agreements, allocation of pension and environmental liabilities, treatment of manufacturing facilities that serve multiple segments and reallocation of corporate overhead. All of those factors could either compress the price a rational buyer will pay or extend the timeline beyond a customary due diligence window.

Regulatory review under the Hart-Scott-Rodino Act is a procedural rather than substantive concern given Ancora is a financial acquirer rather than a strategic competitor, but state-level and cross-border filings would still apply given BAS’s international footprint. Financing is a further question, notwithstanding Ancora’s disclosure that the offer would not carry a financing contingency. The firm has not disclosed the specific structure of committed debt or equity co-investment behind a $1.1 billion to $1.2 billion cheque, and any acquirer of a discrete industrial platform typically needs to demonstrate financing sources acceptable to a target board before a definitive agreement is signed. Finally, there is board and shareholder approval risk on H.B. Fuller’s own side. A material divestment of a reporting segment would almost certainly require formal board approval and could trigger shareholder consent thresholds depending on interpretation of Minnesota corporate law and the terms of H.B. Fuller’s own governance documents.

How does the Ancora campaign reshape the 2027 proxy setup at H.B. Fuller Company?

The bid is inseparable from the governance overhang. Ancora has told shareholders it prefers to work constructively, citing prior engagements at Berry Global Group, Inc., C.H. Robinson Worldwide, Inc. and Mueller Water Products, Inc. as templates for behind-the-scenes value creation, and referencing higher-profile campaigns at Americold Realty Trust and Warner Bros. as evidence of its ability to escalate when required. In the June 24 statement condemning the AMS deal, Ancora explicitly told shareholders that H.B. Fuller’s staggered board structure would not deter it from continuing to pursue a strategic review. A staggered board structure means directors serve staggered multi-year terms and only a portion of the board is up for election in any given year, which slows any activist attempt to gain majority board control.

The August 12 bid changes the conversation heading into 2027 in two ways. First, it converts an argument about capital-allocation philosophy into a concrete transaction the board must be seen to evaluate on the record. A board that refuses to engage with a written all-cash proposal from a shareholder for a discrete segment risks a more difficult conversation with proxy advisers such as Institutional Shareholder Services and Glass Lewis. Second, it establishes Ancora as a credible transaction counterparty rather than only a critic, which is likely to make it harder for the board to characterise the campaign as narrow shareholder posturing. The board’s response, and particularly whether it engages Ancora directly or launches its own strategic review with a broader auction of the segment, will set the tone for the annual meeting cycle.

What has changed and what remains unresolved after Ancora’s public bid for BAS?

What has changed is that a governance dispute now has a specific transaction attached to it, at a size that meaningfully affects H.B. Fuller’s post-AMS capital structure. Ancora has moved from opposition to proposal, given the board a document to evaluate and set a public price benchmark for the segment. What remains unresolved is whether the board will engage with the offer, run a competing process to test the market for a fuller price, defend the existing three-segment portfolio, or reject the bid outright and force the dispute back into the proxy channel.

The next measurable proof point is H.B. Fuller’s formal response, which is likely within the next several weeks once the board completes its financial and legal review. A more informative proof point will be the company’s third-quarter fiscal 2026 result, expected in late September or early October, which will show whether BAS revenue momentum from the second quarter has continued and whether management is willing to speak publicly about portfolio strategy in the AMS integration context. Beyond that, the closing of the AMS acquisition and the trajectory of net leverage in the first two quarters after completion will determine whether Ancora’s argument that BAS proceeds are needed to accelerate deleveraging remains compelling to institutional shareholders. The thesis strengthens for Ancora if the board is seen to have refused to engage with a credible cash offer at a reasonable multiple; it weakens if H.B. Fuller runs a defensive market check that produces a higher price or if BAS growth accelerates enough to make the current bid look opportunistic.

Key takeaways from Ancora’s $1.2 billion bid for H.B. Fuller’s Building Adhesives unit

• Ancora Holdings Group has proposed to acquire H.B. Fuller’s Building Adhesive Solutions segment for $1.1 billion to $1.2 billion in all cash, without a financing contingency.
• The proposal was first made privately on July 7, 2026 and disclosed publicly on August 12, 2026 through a combative letter signed by Fred DiSanto and James Chadwick.
• H.B. Fuller has confirmed receipt and said its board will evaluate the offer with financial and legal advisers, but has taken no substantive position.
• The bid follows Ancora’s public opposition to H.B. Fuller’s recommended £715 million acquisition of Advanced Medical Solutions Group, which was announced in June and takes pro forma net leverage to 4.0 times.
• BAS generated approximately $850 million in fiscal 2024 revenue and roughly $130 million in adjusted EBITDA, with second-quarter fiscal 2026 revenue up 9.4 percent year on year to $245.2 million.
• Ancora’s range implies an enterprise-value multiple of roughly 8.5 to 9.2 times fiscal 2024 BAS adjusted EBITDA, a full but defensible price for a fragmented building-products platform.
• A BAS divestment at that range would give H.B. Fuller a path to return to its 2.5 to 3.0 times leverage target faster than the two-year deleveraging plan disclosed with the AMS transaction.
• Execution and carve-out complexity is material because BAS was itself only assembled at the start of fiscal 2025 after the Flooring divestiture.
• Ancora has referenced prior engagements at Berry Global, C.H. Robinson and Mueller Water Products as constructive templates and has previously signalled a 2027 proxy fight at H.B. Fuller.
• The near-term catalysts are the board’s formal response, the third-quarter fiscal 2026 result and any decision to run a competing strategic review of the BAS segment.